[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100566297":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":41,"responsibleParty":61,"collaborators":26,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":74,"minAge":75,"maxAge":26,"enrollmentInfo":76,"targetDuration":26,"studyType":79,"phases":80,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":44,"whyStopped":26,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Mazandaran University of Medical Sciences","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"intervention","EXPERIMENTAL","Intervention group will be treat with ASA 325 mg stat and ticagrelor 180 mg stat, then ASA 80 mg daily and ticagrelor 90 mg BID for 30 days. Then ticagrelor 60 mg BID and ASA 80 mg daily until the end of month 6.",[13],"Drug: Ticagrelor 60 + Aspirin",{"label":15,"type":16,"description":17,"interventionNames":18},"comparator","ACTIVE_COMPARATOR","Comparator group will be treat with ASA 325 mg stat and ticagrelor 180 mg stat, then ASA 80 mg daily and ticagrelor 90 mg BID for 30 days. Then ASA 80 mg daily until the end of month 6.",[19],"Drug: Ticagrelor 90 + aspirin",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Ticagrelor 60 + Aspirin","Ticagrelor 90 mg BID plus ASA 80 mg daily for 1 month and then ticagrelor 60 mg BID plus ASA 80 mg daily until the end of month 6.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Ticagrelor 90 + aspirin","ticagrelor 90 mg BID plus ASA 80 mg daily for 1 month.",[15],[32,37],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Athena Sharifi Razavi, MD","CONTACT","+989113510136","athena.sharifi@yahoo.com",{"name":38,"role":34,"phone":39,"phoneExt":26,"email":40},"Nasim Tabrizi, MD","00989111263538","nasimtabrizi@gmail.com",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Mazandaran province, Sari,Iran","RECRUITING","Sari","Mazandaran","4817844718","Iran","IR",{"type":51,"coordinates":52},"Point",[53,54],53.06009,36.56332,{"lat":54,"lon":53},[57,59],{"name":58,"role":34,"phone":35,"phoneExt":26,"email":36},"Athena Sharifi-Razavi",{"name":60,"role":34,"phone":26,"phoneExt":26,"email":26},"Nasim Tabrizi",{"type":62,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Athena Sharifi Razavi","Dr. Athena Sharifi Razavi","100566297","phase-2-ticagrelor-based-de-escalation-of-dual-antiplatelet-therapy-in-ischemic-stroke-100566297",false,"NCT06653348","Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke","De-Escalation of Dual Antiplatelet Therapy With Ticagrelor and Aspirin in Non-disabling Non-cardioembolic Ischemic Stroke or High Risk TIA Patients: A Randomized, Outcome Assessor Blind, Controlled Trial","DEDAPT-TICA","Inclusion Criteria:\n\n* signing inform consent,\n* recent ischemic stroke within 24 h,\n* diagnosed by brain CT or MRI mild stroke with NIHSS =\\\u003C8 and no evidence of large infarct in brain imaging\n* high risk TIA with ABCD \\>4,\n* no cardioembolic source such as low E\u002FF, MS, AF ,...\n* no specific etiology such as dissection, vasculitis, ...\n* no carotid stenosis \\> 50 % in side of involvement\n\nExclusion Criteria:\n\n* history of hypersensitivity to consumptive drug\n* any indication for anticoagulant therapy\n* acute phase treatment with intravenous thrombolysis or thrombectomy\n* any contraindication for consumptive drug\n* history of intracranial hemorrhage\n* history of GI bleeding during past 6 m\n* candidate for endarterectomy\n* history of coagulopathy\n* active hemorrhagic diathesis during randomization",true,"ALL","40 Years",{"count":77,"type":78},100,"ESTIMATED","INTERVENTIONAL",[81,82],"PHASE2","PHASE3","This is a randomized, controlled, outcome assessor blind, parallel group design pilot study on 100 patient with diagnosis of ischemic stroke admitted in Bou-Ali Sina Hospital, Sari,Iran.The aim of study is to compare the efficacy of 90 mg ticagrelor BID plus aspirin for 1 month and 60 mg ticagrelor BID plus aspirin for 6 months in reduce of non-disabling non-cardioembolic ischemic stroke or high risk TIA recurrence during first 12 months.",[85,86],"Ischemic Stroke","Transient Ischemic Attack",[88,89,90,91,92,93,94],"ischemic stroke","non-cardioembolic","non-disabling","TIA","Ticagrelor","de-escalation","dual antiplatelet therapy","2025-04-23",{"date":97,"type":98},"2025-04-27","ACTUAL",{"date":100,"type":98},"2024-04-01",{"date":102,"type":78},"2026-08-01",{"name":5,"class":6},1]